Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 108.69

From 52W high−20.06%

Volume3.57M

Market capCNY 31.19B

P/E (TTM)−191.4x

P/S (TTM)19.1x

Div yield—

Key dataSep 18, 2026

Open

CNY 108.69

From 52W high

−20.06%

Volume

3.57M

Market cap

CNY 31.19B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

−191.4x

RSI (14)

45.1

MomentumView details →

1D Return

−8.45%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−191.4x

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

19.1x

P/B (TTM)

18.1x

ProfitabilityView details →

Gross Margin

94.50%

Net Margin

32.16%

EBITDA Margin

−7.76%

ROE (TTM)

29.07%

ROA (TTM)

13.50%

Asset Turnover

0.47x

GrowthView details →

Revenue YoY

+161.37%

EPS YoY

+490.40%

FCF YoY

+505.15%

Revenue CAGR 3Y

+38.92%

EPS CAGR 3Y

−19.23%

EBITDA YoY

—

MomentumView details →

1D Return

−8.45%

YTD Return

—

1Y Return

—

RSI (14)

45.1

vs 50D SMA

−8.55%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.55x

Current Ratio

2.36x

Quick Ratio

2.23x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

CNY 0.03

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

−0.50%

Financials snapshotView financials →

Revenue (TTM)

1.55B

Net Income (TTM)

497.93M

Op. CF (TTM)

814.89M

Next earningsOct 26, 2026 →

Latest newsMore news →

Zelgen Biopharmaceuticals announced that its self-developed injection of human thyrotropin beta (brand: Zesuning) for a new indication has been accepted for marketing application review by China's National Medical Products Administration.14d ago

Zelgen Pharmaceuticals reported first-half 2026 revenue of 550 million yuan from four marketed innovative drugs, up 44.3% year-on-year.33d ago

Similar companies

Alnylam Pharmaceuticals, Inc.ALNY Shanghai Henlius Biotech, Inc.02696.HK Roivant Sciences Ltd.ROIV Simcere Pharmaceutical Group Limited02096.HK 万泰生物603392.SH 君实生物-U688180.SH Find similar companies →

Latest newsMore news →

Zelgen Biopharmaceuticals announced that its self-developed injection of human thyrotropin beta (brand: Zesuning) for a new indication has been accepted for marketing application review by China's National Medical Products Administration.14d ago Zelgen Pharmaceuticals reported first-half 2026 revenue of 550 million yuan from four marketed innovative drugs, up 44.3% year-on-year.33d ago Zelgen Biopharmaceuticals disclosed H1 revenue of 1.205 billion yuan, up 220.88% year-over-year, with net profit of 640 million yuan, turning from loss to profit.35d ago